Crispr Therapeutics Said On June 8, Co, Vertex Said FDA Accepted BLA For EXA-CEL, Being Investigated For Treatment Of SCD, TDT In Patients Ages 12 To 35
Portfolio Pulse from Charles Gross
Crispr Therapeutics and Vertex announced that the FDA has accepted their BLA for EXA-CEL, a treatment for SCD and TDT in patients aged 12 to 35.
June 09, 2023 | 11:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Crispr Therapeutics' BLA for EXA-CEL, a treatment for SCD and TDT, has been accepted by the FDA.
The FDA's acceptance of the BLA for EXA-CEL is a positive development for Crispr Therapeutics, as it indicates progress in the regulatory process and potential future approval. This could lead to increased revenues and growth for the company, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Vertex's BLA for EXA-CEL, a treatment for SCD and TDT, has been accepted by the FDA.
The FDA's acceptance of the BLA for EXA-CEL is a positive development for Vertex, as it indicates progress in the regulatory process and potential future approval. This could lead to increased revenues and growth for the company, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100